In this webinar hosted by GenomeWeb, IDT customer Nick Wong, a senior research fellow at Monash University, will discuss the development of a high-throughput NGS assay as part of this ancillary research for measuring and investigating CHIP in banked peripheral blood samples collected from the ASPREE clinical trial.
Just how common is clonal hematopoiesis of indeterminate potential (CHIP)? In this study, Wong seeks to answer that question and learn more about its role in other common health problems in the elderly, like heart disease and stroke.
Summary
Clonal hematopoiesis of indeterminate potential (CHIP) describes the development of somatic mutations associated with leukemogenesis in otherwise normal, healthy people and is associated with increased risk of cardiovascular disease and cancer. The ASPREE (ASPirin in Reducing Events in the Elderly) trial randomized 19,114 healthy participants aged 70 years or older to low dose aspirin or a placebo. Participant follow-up is ongoing. Peripheral blood samples from 12,223 participants at study entry and about 10,600 participants at three years provide a unique opportunity to investigate CHIP through an ancillary research study in this cohort.
Presented by
- Nicholas Wong, PhD
Senior Research Fellow
Monash University
- Simon Dunbar
NGS Manager - APAC
Integrated DNA Technologies
Explore our NGS solutions
rhAmpSeq Target Amplicon Sequencing System
Targeted Sequencing Guide